Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Meijer

Showing results (231-240 of 282) with videos related to

Pageof 29
Sort By:
Breast Cancer Research and Treatment|September 2, 2008
CHEK2 1100delC and male breast cancer in the NetherlandsMarijke Wasielewski, Michael A den Bakker, Ans van den Ouweland, et al.
Diabetologia|June 14, 2019
Correction to: Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) studyA Abbasi, E Corpeleijn, E Meijer, et al.
The Netherlands Journal of Medicine|May 24, 2007
Single-centre experience with nonmyeloablative allogeneic stem cell transplantation in patients with multiple myeloma: prolonged remissions inducedS van Dorp, E Meijer, N W C J van de Donk, et al.
Cancer Research|July 17, 2001
High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancerJ A Foekens, H A Peters, N Grebenchtchikov, et al.
Plos One|December 31, 2015
A Method to Correlate mRNA Expression Datasets Obtained from Fresh Frozen and Formalin-Fixed, Paraffin-Embedded Tissue Samples: A Matter of ThresholdsDana A M Mustafa, Anieta M Sieuwerts, Marcel Smid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998
Prognostic significance of cathepsins B and L in primary human breast cancerJ A Foekens, J Kos, H A Peters, et al.
Cancer Letters|March 29, 2016
GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent diseaseJingjing Liu, Wendy J C Prager-van der Smissen, Maxime P Look, et al.
Molecular Oncology|August 2, 2014
Evaluation of the ability of adjuvant tamoxifen-benefit gene signatures to predict outcome of hormone-naive estrogen receptor-positive breast cancer patients treated with tamoxifen in the advanced settingAnieta M Sieuwerts, Maria B Lyng, Marion E Meijer-van Gelder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 1998
p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancerE M Berns, J G Klijn, W L van Putten, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2005
How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective studyAnieta M Sieuwerts, Marion E Meijer-van Gelder, Mieke Timmermans, et al.
Pageof 29

Showing results (231-240 of 282) with videos related to

Sort By:
Pageof 29
Breast Cancer Research and Treatment|September 2, 2008
CHEK2 1100delC and male breast cancer in the NetherlandsMarijke Wasielewski, Michael A den Bakker, Ans van den Ouweland, et al.
Diabetologia|June 14, 2019
Correction to: Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) studyA Abbasi, E Corpeleijn, E Meijer, et al.
The Netherlands Journal of Medicine|May 24, 2007
Single-centre experience with nonmyeloablative allogeneic stem cell transplantation in patients with multiple myeloma: prolonged remissions inducedS van Dorp, E Meijer, N W C J van de Donk, et al.
Cancer Research|July 17, 2001
High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancerJ A Foekens, H A Peters, N Grebenchtchikov, et al.
Plos One|December 31, 2015
A Method to Correlate mRNA Expression Datasets Obtained from Fresh Frozen and Formalin-Fixed, Paraffin-Embedded Tissue Samples: A Matter of ThresholdsDana A M Mustafa, Anieta M Sieuwerts, Marcel Smid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998
Prognostic significance of cathepsins B and L in primary human breast cancerJ A Foekens, J Kos, H A Peters, et al.
Cancer Letters|March 29, 2016
GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent diseaseJingjing Liu, Wendy J C Prager-van der Smissen, Maxime P Look, et al.
Molecular Oncology|August 2, 2014
Evaluation of the ability of adjuvant tamoxifen-benefit gene signatures to predict outcome of hormone-naive estrogen receptor-positive breast cancer patients treated with tamoxifen in the advanced settingAnieta M Sieuwerts, Maria B Lyng, Marion E Meijer-van Gelder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 1998
p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancerE M Berns, J G Klijn, W L van Putten, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2005
How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective studyAnieta M Sieuwerts, Marion E Meijer-van Gelder, Mieke Timmermans, et al.
Pageof 29